Patched homolog 1 gene (PTCH1) expression and the ratio of PTCH1 to Smoothened (SMO) expression have been proposed as prognostic markers of the response of chronic myeloid leukemia (CML) patients to imatinib. Here, PTCH1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.